Latest Commercialization News

OncoSil Medical reported a 60% year-on-year increase in dose sales in Q3 FY26, boosted by expanding treatment centres and advancing clinical trials, while cost-cutting and a new manufacturing facility aim to underpin growth.

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.

Red Metal Limited is progressing key rare earth and base metal projects across Australia, securing government grants and proposing a major Maronan Metals share distribution to shareholders.

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.

Dimerix’s blinded review of its pivotal ACTION3 Phase 3 trial confirms over 90% statistical power to detect DMX-200’s effect on proteinuria, reinforcing the study’s design and regulatory pathway.

Centaurus Metals has secured a binding offtake deal with Glencore and attracted up to US$320 million in financing offers for its Jaguar Nickel Project, while advancing exploration and pilot testing at its Brazilian copper-gold and iron ore assets.

VBX Limited has more than doubled the Measured and Indicated Mineral Resource at its Wuudagu bauxite project to 131.9 million tonnes with improved grades, while also enhancing its Definitive Feasibility Study scope and securing additional funding.

1414 Degrees (ASX:14D) advances its SiNTL silicon anode technology, aiming to disrupt lithium-ion batteries in the rapidly expanding drone and UAV sector with higher capacity and faster charging.

Victory Metals has unlocked a rare metallurgical feat at North Stanmore, achieving a globally top-tier 72% heavy rare earth ratio and unveiling a second revenue stream from zircon-hafnium concentrate using a low-cost gravity separation process.

PYC Therapeutics fortified its balance sheet by $600 million and progressed key RNA therapeutic trials in Q1 2026, setting the stage for pivotal clinical data and regulatory submissions.

Pivotal Metals is progressing a mineral resource update and scoping study for its Horden Lake copper project in Québec, targeting a large open-pit operation with strong cashflow potential amid record copper prices.

Cambium Bio has clinched FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development complexity, while bolstering its cash position through a A$2.4 million strategic placement by major shareholder ZYBT.